ADM, a global leader in nutrition and agricultural origination and processing, announced on Nov. 2nd a significant expansion of its broad portfolio of health and wellness products and solutions with an agreement to purchase US-based Deerland Probiotics & Enzymes.
“The microbiome represents one of ADM’s six strategic growth platforms, and with global demand for health and wellness products estimated at more than $775 billion, the investment represents a significant step forward for ADM,” said ADM Chairman and CEO Juan Luciano.
“Deerland Probiotics & Enzymes is a leader in probiotic, prebiotic and enzyme technology, with global sales and manufacturing in the U.S. and Europe, and is a perfect fit for our growing portfolio of functional ingredients and solutions for health-conscious consumers. We expect the addition of the Deerland capabilities and portfolio to deliver synergies for our Health & Wellness business and support growth across our Nutrition business unit.”
Deerland Probiotics & Enzymes is a trusted global provider of probiotic and dietary supplements using probiotic, prebiotic, and enzyme technology, including 12 branded product lines serving customers in areas including digestive health, immune health, women’s health, food intolerance, sports nutrition, cellular repair, and systemic and cardiovascular health. The company’s products and solutions include spore probiotics, which offer enhanced stability for a wider use in food and beverage, pet nutrition and supplement applications. Based in Kennesaw, Georgia, U.S., Deerland operates five manufacturing facilities, one fermentation facility, and eight R&D and quality control laboratories globally.
“The hand-in-glove fit of Deerland’s vast portfolio of branded technologies, clinical studies and world-class dosage form production capabilities combined with ADM’s Health and Wellness solutions is strong and unparalleled, allowing us to provide our dietary supplement, food/beverage and companion animal customers with a much broader array of products and capabilities,” said Scott Ravech, Deerland Probiotics & Enzymes CEO. “The Deerland team could not be more excited at the opportunity to be a part of the ADM family.”
The Deerland acquisition is the latest in a series of ADM strategic investments to build a full-scale global Health & Wellness business to help meet fast-growing demand for food, beverages and supplements that enhance health and wellbeing. Growth initiatives have included acquisitions like Protexin and Biopolis, organic capacity investments to expand probiotics production at our Valencia facility, and our recently-announced joint venture and previous partnership with Vland. With the revenue contribution from the addition of Deerland, annualized revenue for Health & Wellness will exceed $500 million.
The transaction, which is subject to regulatory approval, is expected to be completed in the coming weeks; when that occurs, Deerland’s approximately 320 colleagues will transfer to ADM.